Le Lézard
Classified in: Health
Subject: TRADE SHOWS/SEMINARS/WEBINARS

NuLife to Present at Source Capital Group Disruptive Growth & Healthcare Conference


SAN CLEMENTE, CA--(Marketwired - January 25, 2017) - NuLife Sciences (OTCQB: NULF) through the Company's wholly-owned subsidiary, NuLife BioMed, Inc. today announced that management will present at the Source Capital Group 2nd Annual Disruptive Growth & Healthcare Conference being held February 15th and 16th in New York.

NuLife management will host one-on-one meetings throughout the day and is scheduled to present as follows:

Source Capital Group 2nd Annual Disruptive Growth & Healthcare Conference
Presentation: Wednesday, Feb 15 at 1:45-2:10 PM
Location: Convene, 730 Third Avenue, New York City, Track 1 - Tribeca

About NuLife Sciences

NuLife Sciences (OTCQB: NULF) is a biomedical company focused on advancing human organ transplant technology and medical research. NuLife has a patent protected unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal experiments on its pathway to commercialization.

Safe Harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.


These press releases may also interest you

at 05:32
According to the latest BCC Research study, the demand for Peptide Synthesis: Global Markets is growing from $90.1 billion in 2023 to $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% from 2023 through 2028. The...

at 05:03
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI In Life Science Analytics Market ? By Component (Software, Hardware, Services), By Deployment (On-premise, Cloud), By Application (Research and...

at 05:02
According to the latest BCC Research study, the demand for Global Markets and Technologies for Nanofibers is growing from $2.9 billion in 2023 to $9.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.0% from 2023 through...

at 05:00
AxisCare, a leading provider of home care software, today released the findings of its independent survey, The Future of Homecare, conducted by Leading Home Care...a Tweed Jeffries company and the Homecare CEO Forum. The survey...

at 04:59
AMSilk GmbH ("AMSilk"), a frontrunner in advanced biomaterials made from spider silk-based proteins, today announces that Gudrun Vogtentanz, Chief Scientific Officer, will participate in a panel discussion titled 'Advancing the Bioeconomy:...

at 04:54
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global  In Vitro Diagnostic (IVD) Reagents Market ? (By Type (Antibodies, Purified Proteins and Peptides, Oligonucleotides, Others), By Technology (Immunoassay,...



News published on and distributed by: